Table 3.
Odds ratios (OR) for IVF outcomes based on quartiles of HOMA-β in PCOS.
| IVF outcomes | Quartiles of HOMA-β | ||||
|---|---|---|---|---|---|
| Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | P for trend | |
| Biochemical pregnancy rate | |||||
| Model 1 | 1.00 (Reference) | 1.26 (0.90-1.75) | 1.16 (0.83-1.62) | 1.14 (0.82-1.59) | 0.54 |
| Model 2 | 1.00 (Reference) | 1.24 (0.88-1.75) | 1.14 (0.80-1.63) | 1.12 (0.77-1.62) | 0.55 |
| Model 3 | 1.00 (Reference) | 1.31 (0.92-1.86) | 1.19 (0.83-1.71) | 1.16 (0.78-1.72) | 0.39 |
| Clinical pregnancy rate | |||||
| Model 1 | 1.00 (Reference) | 1.13 (0.82-1.55) | 1.03 (0.75-1.42) | 1.17 (0.85-1.61) | 0.47 |
| Model 2 | 1.00 (Reference) | 1.11 (0.80-1.55) | 1.01 (0.71-1.42) | 1.14 (0.80-1.62) | 0.48 |
| Model 3 | 1.00 (Reference) | 1.20 (0.85-1.68) | 1.06 (0.75-1.51) | 1.23 (0.84-1.80) | 0.35 |
| Ectopic pregnancy rate | |||||
| Model 1 | 1.00 (Reference) | 1.50 (0.25-9.01) | 2.52 (0.49-13.07) | 2.01 (0.37-11.04) | 0.34 |
| Model 2 | 1.00 (Reference) | 1.46 (0.23-9.18) | 2.53 (0.44-14.61) | 1.96 (0.31-12.65) | 0.34 |
| Model 3 | 1.00 (Reference) | 1.53 (0.24-9.78) | 2.27 (0.40-13.04) | 1.34 (0.21-8.63) | 0.32 |
| Miscarriage rate | |||||
| Model 1 | 1.00 (Reference) | 2.41 (1.24-4.71) | 2.54 (1.30-4.96) | 4.37 (2.31-8.27) | <0.001 |
| Model 2 | 1.00 (Reference) | 1.85 (0.90-3.80) | 2.13 (1.07-4.24) | 3.09 (1.53-6.24) | <0.001 |
| Model 3 | 1.00 (Reference) | 1.94 (0.96-3.93) | 1.78 (0.86-3.70) | 2.66 (1.27-5.55) | <0.001 |
| Live birth rate | |||||
| Model 1 | 1.00 (Reference) | 0.90 (0.65-1.24) | 0.78 (0.57-1.08) | 0.70 (0.51-0.97) | 0.02 |
| Model 2 | 1.00 (Reference) | 0.95 (0.68-1.32) | 0.87 (0.61-1.23) | 0.79 (0.55-1.13) | 0.02 |
| Model 3 | 1.00 (Reference) | 1.04 (0.74-1.46) | 0.92 (0.65-1.31) | 0.91 (0.62-1.33) | 0.04 |
Model 1 was unadjusted. Model 2 was adjusted for age and BMI. Model 3 was further adjusted for SBP, TG, HDL and basal T levels. All the confounding factors were log transformed. OR, odds ratio; IVF, in-vitro fertilization; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β cell function; PCOS, polycystic ovary syndrome.